Researchers in the laboratories of Prof. Stanley Cohen and Prof Tzu-Hao Cheng have discovered that Supt4h is a potential therapeutic target for reducing toxicity and restoring the functionality of deleterious proteins in Huntington's (HD) and other polyQ diseases.